Chief Executive Officer
Gavin was appointed CEO of Biosceptre International Ltd in October 2012, having been a Board member since 2009. Prior to taking the CEO role at Biosceptre, Gavin was General Manager of a family-held investment fund with a strong biotech focus, where he oversaw investment in a range of biotechs and served as a non-executive Director on a number of Biotech boards. Biosceptre was a key investment within that fund. Gavin previously founded a boutique transaction services company and has significant experience in M&A, particularly integrating businesses post transaction. Gavin developed a reputation for delivering value by commercialising previously unseen opportunities and has been employed internationally in Australia, New Zealand, England, USA and Hong Kong, with experience in cross-border transactions and investments.
Shaun McNulty, PhD
Chief Scientific Officer
Shaun joined Biosceptre in January 2014 with over 20 years of experience working in the Pharmaceutical and Biotechnology sectors across a range of functions, from target identification, drug discovery and portfolio management to product and commercial development. Shaun is experienced in strategic planning and brings broad industry understanding to the scientific and commercial sides of the business.
Having obtained his doctorate from the University of York, Shaun undertook 5 years of post-doctoral study at the University of Cambridge. He then held positions at GSK, Pfizer and Syntaxin, managing a number of scientific teams, international drug discovery projects and drug development portfolios. Shaun joined ImmBio in 2008, establishing scientific links and the commercial strategy that led to the company obtaining multiple grants to develop its vaccine products. Currently, Shaun directs Biosceptre International’s portfolio of drugs through research and clinical development stages.
Paul de Souza
Chief Medical Officer
Professor Paul De Souza is Foundation Chair of Medical Oncology, School of Medicine, at Western Sydney University; a conjoint Professor in the Faculty of Medicine, UNSW; and an Honorary Professor of the NHMRC Clinical Trials Centre, University of Sydney. He has over 20 years’ experience in caring for patients, especially those with brain cancer and genitourinary cancer, and clinical trials experience over the same period, including a stint as a Clinical Research Physician in a global research-based pharmaceutical company.
Pauls’ role is oversight of the execution of the clinical trial protocol for Biosceptre’s innovative therapeutic cancer therapies during Phase I trials in Australia.
Daniel Barton BSc Llb
Director Business Development
Daniel Barton is Director of Business Development for Biosceptre, working across strategy and delivery, and applying broad professional skills in legal, administration, product development and marketing. Daniels’ academic background is molecular biochemistry and intellectual property. He has founded, run, and sold start ups, held P&L and board reporting roles in listed companies, and led development teams, collaborated with research groups, and commissioned external and internal product development and production teams.
Senior Manager – Legal & Compliance
Brad joined Biosceptre as Senior Manager – Legal & Compliance in May 2013 after five years with a private international investment fund. With practical knowledge in both financial management and legal documentation, Brad gained hands on experience across a broad range of cross-border transactions including mergers and acquisitions, debt financing and equity investments, primarily in the life sciences sector. Brad holds a Masters of Business Law from the University of Sydney and a Bachelor of Business Administration from Macquarie University.